Novavax logo
Novavax
NVAX | NASDAQ
Chart Builder DCF Calculator
$8.06
-$0.46 (-5.45%)
At close: Nov 16, 2026, 4:00 PM ET
$8.07
+$0.01 (+0.14%)
After-hours: Nov 16, 2026, 7:50 PM ET

Novavax Company Profile

Company profile explained

Company Profile

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Key Executives

Name Position
John Charles Jacobs President, Chief Executive Officer & Director
James Patrick Kelly Executive Vice President, Chief Financial Officer & Treasurer
Mark Casey Executive Vice President, Chief Legal Officer & Corporate Secretary
Richard Crowley Executive Vice President & Chief Operating Officer
Elaine O'Hara Executive Vice President & Chief Strategy Officer
Erika S. Trahan Associate Director of Investor & Public Relations
Ian J. Watkins Executive Vice President & Chief Human Resources Officer
Naina Zaman Director of Investor Relations
Silvia Taylor Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden
Troy Morgan Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 16, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 16, 2026 SC 13D/A [Amend] Filing
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 S-8 Filing
Aug 06, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
Jun 23, 2026 4 Filing
View All SEC Filings ➞
Novavax
Novavax logo
Country United States
IPO Date Dec 5, 1995
Industry Biotechnology
Sector Healthcare
Employees 749
CEO John Charles Jacobs

Contact Details

21 Firstfield Road Gaithersburg, Maryland 20878 United States

Stock Details

Ticker Symbol NVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001000694
CUSIP Number 670002401
ISIN Number US6700024010
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.